Ares Financial Consulting
XENE icon

Ares Financial Consulting’s Xenon Pharmaceuticals XENE Stock Holding History

Ares Financial Consulting’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12
Closed -$724 – 1142
2026
Q2 		$724 Buy
+12
New +$666 ﹤0.01% 1051

Other funds holding XENE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ares Financial Consulting's XENE Position: Q3 2026 in Review

Ares Financial Consulting sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 12 shares — an estimated $724 sold.

Ares Financial Consulting first reported a position in XENE in Q2 2026 and held it in 1 quarter. The position peaked at $724 in Q2 2026. 100 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Ares Financial Consulting reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 12 Xenon Pharmaceuticals shares in Q3 2026, an estimated $724.
  • Ares Financial Consulting first reported a position in Xenon Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Xenon Pharmaceuticals position peaked at $724 in Q2 2026.
  • 100 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.